Distributor inventory | Tablet
Voglibose 0.2 mg
Management of type 2 diabetes mellitus to reduce post‑meal (postprandial) blood glucose; used alone or with other antidiabetic medicines along with diet and exercise.
Voglibose is an alpha‑glucosidase inhibitor that delays breakdown and absorption of carbohydrates in the intestine. This slows the rise in blood glucose after meals and reduces postprandial hyperglycaemia.
Tablet for oral use. Usually taken just before meals (or with the first bite of food) as prescribed. Follow diet and exercise advice; do not skip meals when taking antidiabetic medicines.
Common side effects of VOGIFORMIN 0.2MG TAB may include:
Use with caution in liver disease; periodic liver function monitoring may be advised. Not recommended in patients with inflammatory bowel disease, intestinal obstruction, chronic intestinal diseases with marked digestion/absorption disorders, or severe renal impairment unless advised by a doctor. Risk of hypoglycaemia increases when combined with insulin or sulfonylureas—carry glucose/dextrose for treatment (table sugar/sucrose may be less effective due to mechanism). Seek medical help for severe abdominal symptoms, jaundice, or persistent diarrhoea.
